Volume | 10,918 |
|
|||||
News | - | ||||||
Day High | 11.93 | Low High |
|||||
Day Low | 11.39 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pieris Pharmaceuticals Inc | PIRS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.50 | 11.39 | 11.93 | 11.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,096 | 10,918 | $ 11.72 | $ 127,968 | - | 10.888 - 80.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:58:28 | 1 | $ 11.87 | USD |
Pieris Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.17B | 98.85M | - | 42.81M | -24.54M | -0.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pieris Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PIRS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.32 | 12.93 | 11.04 | 11.66 | 800,229 | -0.42 | -3.41% |
1 Month | 15.20 | 15.20 | 11.04 | 12.88 | 518,949 | -3.30 | -21.71% |
3 Months | 14.392 | 22.32 | 11.04 | 14.68 | 681,462 | -2.49 | -17.32% |
6 Months | 19.168 | 23.20 | 10.888 | 14.79 | 580,095 | -7.27 | -37.92% |
1 Year | 64.216 | 80.80 | 10.888 | 25.08 | 1,440,296 | -52.32 | -81.47% |
3 Years | 182.40 | 492.00 | 10.888 | 214.22 | 1,710,850 | -170.50 | -93.48% |
5 Years | 235.20 | 496.00 | 10.888 | 223.29 | 1,220,697 | -223.30 | -94.94% |
Pieris Pharmaceuticals Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States. |